about
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK inhibition as an Effective StrategyPoor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapyCheckpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy
P50
description
researcher (ORCID 0000-0002-1681-5883)
@en
wetenschapper
@nl
name
Pallawi Torka
@en
Pallawi Torka
@nl
type
label
Pallawi Torka
@en
Pallawi Torka
@nl
prefLabel
Pallawi Torka
@en
Pallawi Torka
@nl
P31
P496
0000-0002-1681-5883